v2.4.0.6

Balance Sheets (USD $)	Oct. 30, 2012	Jul. 31, 2012
Current Assets
Cash	$ 5,846	$ 24,041
Prepaid expenses and other current assets	0	9,746
Other assets	11,382	11,382
Total Current Assets	17,228	45,169
Property and equipment, net	12,392	14,204
Deferred financing costs	226	20,485
Total Assets	29,846	79,858
Current Liabilities
Accounts payable	602,719	583,610
Accrued expenses	264,991	213,079
Derivative liability	1,152,886	1,256,425
Convertible debt, less discount	3,250,000	2,982,877
Accrued interest, convertible debt	487,500	447,432
Total current liability	5,758,096	5,483,423
Accounts payable, net of current portion	444,223	444,223
Accrued retirement benefits	231,250	231,250
Total Liabilities	6,433,569	6,158,896
Stockholders' Deficiency
Preferred stock, $0.001 par value	0	0
Common stock, $.001 par value	53,824	53,824
Additional Paid-in Capital	100,923,761	100,874,628
Accumulated deficit	(107,381,308)	(107,007,490)
Total Stockholders' deficiency	(6,403,723)	(6,079,038)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	$ 29,846	$ 79,858

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.

Tamir Biotechnology, Inc. 10-Q